Mineralys Therapeutics, Inc. Common Stock (MLYS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $27.88 (-0.36%), Market cap $2.18B, 52-week low–high $12.87 ~ $47.33.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Financial statements, price targets, institutional (13F) holdings and related news for Mineralys Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Mineralys Therapeutics, Inc. Common Stock trades at $27.88 (-0.36%). Real-time quotes and charts are available on BlackAll Trade.
Mineralys Therapeutics, Inc. Common Stock has a market cap of about $2.18B.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary,